Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar

References

• GoASMozaffarianDRogerVAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2014 update: a report from the American Heart AssociationCirculation20141293e28e29224352519
   PubMed Web of Science ®Google Scholar
• DavìGPatronoCPlatelet activation and atherothrombosisN Engl J Med2007357242482249418077812
   PubMed Web of Science ®Google Scholar
• Circulation [webpage on the Internet]2014AHA/ACC Guidelines for the Management of Patients with Non-ST Elevation Acute Coronary Syndrome: A Report of the American College of Cardiology Foundation/American Heart association Task Force on Practice Guidelines Available from: http://circ.ahajournals.org/content/early/2014/09/22/CIR.0000000000000133Accessed October 7, 2014
   Google Scholar
• O’GaraPTKushnerFGAscheimDD2013 ACCF/AHA guideline for the management of ST elevation myocardial infarctionCirculation2013127e362e42523247304
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRClopidogrel in Unstable Angina to Prevent Recurrent Events Trial InvestigatorsEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med2001345749450211519503
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJClopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) InvestigatorsEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet2001358928152753311520521
   PubMed Web of Science ®Google Scholar
• SabatineMSCannonCPGibsonCMCLARITY-TIMI 28 InvestigatorsAddition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevationN Engl J Med2005352121179118915758000
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P450 genetic polymorphisms and the response to prasugrel relationship to pharmacokinetics, pharmacodynamic, and clinical outcomesCirculation2009119192553256019414633
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHPrasugrel versus clopidogrel in patients with acute coronary syndromeN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• WallentinLRichardBCBudajATicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• BhattDLStoneGWMahaffeyKWEffect of antiplatelet inhibitor with cangrelor during PCI on ischemic eventsN Engl J Med2013368141303131323473369
   PubMed Web of Science ®Google Scholar
• ChackalamannilSXiaYGreenleeWJDiscovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agentsJ Med Chem200548195884588716161991
   PubMed Web of Science ®Google Scholar
• ChackalamannilSThrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effectsJ Med Chem200649185389540316942011
   PubMed Web of Science ®Google Scholar
• ChackalamannilSWangYGreenleeWJDiscovery of a noval, orally active himbacine-based thrombin receptor antagonist (SCH530348) with potent antiplatelet activityJ Med Chem200851113061306418447380
   PubMed Web of Science ®Google Scholar
• AngiolilloDCapranzanoPPharmacology of emerging novel platelet inhibitorsAm Heart J2008156210S15S
   Web of Science ®Google Scholar
• Merck [webpage on the Internet]Zontivity™ [prescribing information] Available from: http://www.merck.com/product/usa/pi_circulars/z/zontivity/zontivity_pi.pdfAccessed October 10, 2014
   Google Scholar
• FDA [webpage on the Internet]FDA Briefing DocumentCardiovascular and Renal Advisory Committee2014 Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm381327.pdfAccessed November 13, 2014
   Google Scholar
• BehmMOKosoglouTMiltenburgAMMThe absence of a clinically significant effect of food on the single dose pharmacokinetics of vorapaxar, a PAR-1 antagonist, in healthy adult subjectsClin Pharmacol Drug Dev20132431031527121935
   PubMed Web of Science ®Google Scholar
• GhosalALuXPennerNIdentification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonistDrug Metab Dispos2011391303820926621
   PubMed Web of Science ®Google Scholar
• KosoglouTStatkevichPKumarBThe effect of multiple doses of ketoconazole or rifampin on the single- and multiple dose pharmacokinetics of vorapaxarJ Clin Pharmacol201353554054923426761
   PubMed Web of Science ®Google Scholar
• KosoglouTKraftWKKumarBPharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal diseaseEur J Clin Pharmacol20126871049105622315147
   PubMed Web of Science ®Google Scholar
• StatkevichPKosoglouTPrestonRAPharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairmentEur J Clin Pharmacol201268111501150822527342
   PubMed Web of Science ®Google Scholar
• ChintalaMShimizuKOgawaMYamaguchiHDoiMJensenPBasic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic diseaseJ Pharmacol Sci2008108443343819098390
   PubMed Web of Science ®Google Scholar
• TricociPHuangZHeldCTRACER InvestigatorsThrombin receptor antagonist vorapaxar in acute coronary syndromesN Engl J Med20123661203322077816
   PubMed Web of Science ®Google Scholar
• KikkertWJvan GelovenNvan der LaanMHThe prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST segment elevation myocardial infarction: a comparison with the TIMI, GUSTO and ISTH bleeding classificationJ Am Coll Cardiol201463181866187524657697
   PubMed Web of Science ®Google Scholar
• HeldCTricociPHuangZVorapaxar, a platelet thrombin receptor antagonist, in medically managed patients with non-ST segment elevation acute coronary syndrome: results from the TRACER trialEur Heart J Acute Cardiovasc Care20143324625624627331
   PubMedGoogle Scholar
• ValgimigliMTricociPHuangZUsefulness and safety of vorapaxar in patients with non-ST segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial)Am J Cardiol2014114566567325129064
   PubMed Web of Science ®Google Scholar
• CornelJHTricociPLokhnginaYGlycoprotein IIb/IIIa receptor inhibitors in combination with vorapaxar, a platelet thrombin receptor antagonist, among patients with non-ST-segment elevation acute coronary syndromes (from the TRACER trial)Am J Cardiol2015115101325133225776457
   PubMed Web of Science ®Google Scholar
• WhellanDJTricociPChenEVorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (thrombin receptor antagonist for clinical event reduction in acute coronary syndrome)J Am Coll Cardiol201463111048105724211500
   PubMedGoogle Scholar
• TricociPHuangZvan de WerfFVorapaxar with and without thienopyridine use in acute coronary syndromes: results from the TRACER trialEur Heart J20123349549621951627
   PubMedGoogle Scholar
• MahaffeyKWHuangZWallentinLAssociation of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial)Am J Cardiol2014113693694424444781
   PubMed Web of Science ®Google Scholar
• MorrowDABraunwaldEBonacaMPTRA 2P–TIMI 50 Steering Committee and InvestigatorsVorapaxar in the secondary prevention of atherothrombotic eventsN Engl J Med2012366151404141322443427
   PubMed Web of Science ®Google Scholar
• BonacaMPSciricaBMCreagerMAVorapaxar in patients with peripheral artery disease. Results from TRA 2P-TIMI 50Circulation2013127141522152923501976
   PubMed Web of Science ®Google Scholar
• SciricaBMBonacaMPBraunwaldEVorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trialLancet201238098501317132422932716
   PubMed Web of Science ®Google Scholar
• CavenderMASciricaBMBonacaMPVorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events – TIMI 50 trialCirculation2015131121047105325681464
   PubMed Web of Science ®Google Scholar
• BohulaEAAylwardPEBonacaMPEfficacy and safety of vorapaxar with and without a thienopyridine for secondary prevention in patients with previous myocardial infarction and no history of stroke or transient ischemic attack: results from TRA 2°P-TIMI50Circulation2015132201871187926338971
   PubMed Web of Science ®Google Scholar
• SciricaBMBonacaMPBraunwaldEVorapaxar for secondary prevention after myocardial infarction according to aspirin dose – insights from the TRA 2P-TIMI 50 trialCirculation2012126A14508
   Google Scholar
• KosoglouTReydermanLTsengJEffect of food, antacid, and age on the pharmacokinetics of the oral thrombin receptor antagonist vorapaxar (sch 530348) in healthy volunteersClin Pharmacol Drug Dev20132322323027121783
   PubMed Web of Science ®Google Scholar
• BakerNVLipinskiMJLhermusierTWaksmanROverview of the 2014 food and drug administration cardiovascular and renal drugs advisory committee meeting about vorapaxarCirculation2014130151287129425287768
   PubMed Web of Science ®Google Scholar
• PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGYA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart surveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar